Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech Ink Deal with U.S. Government for Big Coronavirus Vaccine Purchase

By Prosper Junior Bakiny – Jul 22, 2020 at 10:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Washington will pay $1.95 billion to the companies for 100 million doses of their SARS-CoV-2 vaccine -- if it passes muster.

Pfizer (PFE -0.78%) and BioNtech (BNTX -1.73%) are jointly developing four mRNA-based vaccine candidates for the SARS-CoV-2 coronavirus. And on Wednesday morning, the companies announced that they had signed a deal with the U.S. government's Health and Human Services (HHS) and Defense departments to supply them with at least 100 million doses of whichever candidate earns regulatory approval or emergency use authorization -- assuming one does.

Washington will pay the partners $1.95 billion upon delivery of those 100 million doses. The agreement also gives the government the option to purchase 500 million additional doses. Note that on Monday, the two companies announced a similar (albeit smaller) deal with the U.K. government. 

Pfizer and BioNtech are currently running a phase 1/2 clinical trial for the coronavirus vaccine candidates in the BNT162 program, and they recently released positive study data for BNT162b1 -- the most advanced of the bunch. Further, the healthcare companies plan to start a phase 2b/3 clinical trial by the end of July, pending regulatory approval. That study is expected to enroll up to 30,000 healthy participants, and will test the safety and efficacy of the chosen vaccine candidate. It is also worth noting that the Food and Drug Administration has granted fast-track designation to two of the candidates in the program, BNT162b1 and BNT162b2.

Doctor holding a vial with a sign saying "COVID-19 Vaccine Coronavirus."

Image source: Getty Images.

Pfizer and BioNtech aren't the only ones attempting to develop mRNA-based COVID-19 vaccines -- Moderna (MRNA -4.51%) is too, and it's also well advanced in the development process. That biotech company plans to start a phase 3 clinical trial on July 27 for its lead candidate, mRNA-1273. The pivotal study will enroll about 30,000 participants, and its primary endpoint will be "the prevention of symptomatic COVID-19 disease." As the worldwide efforts to find a vaccine heat up, the next few months will be critical for Pfizer and BioNtech.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.